FDA OKs Patisiran (Onpattro) for Polyneuropathy in hAATR FDA OKs Patisiran (Onpattro) for Polyneuropathy in hAATR

Patisiran is the first FDA-approved treatment for polyneuropathy caused by hATTR and the first RNA-based therapy to treat a rare disease.FDA Approvals
Source: Medscape Pathology Headlines - Category: Pathology Tags: Neurology & Neurosurgery News Alert Source Type: news